Clinical Trials for Stomach Cancer

A Phase I/II Trial of Cabozantinib in Combination with Durvalumab (MEDI4736) with or Without Tremelimumab in Patients with Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.

ClinicalTrials.gov ID: NCT03539822

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory gastrointestinal cancers (gastric adenocarcinoma [CDH17+], colorectal adenocarcinoma, or well-differentiated mid/hindgut NETs) receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of CHM-2101, an autologous third-generation CAR T therapy targeting cadherin-17. Single-arm dose escalation/expansion; bridging chemo allowed between leukapheresis and lymphodepletion.

ClinicalTrials.gov ID: NCT06055439

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory B‑cell non‑Hodgkin lymphoma (any subtype) after ≥2 prior therapies, including those previously treated with CD19 CAR T or ineligible for it, receive a single IV infusion of SynKIR‑310, an autologous CD19‑directed KIR‑CAR T‑cell therapy using a multichain KIR/DAP12 signaling platform designed to enhance persistence and antitumor activity. Includes post‑auto/allo transplant patients (with restrictions) and requires measurable disease and ECOG 0–1.

ClinicalTrials.gov ID: NCT06544265

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic CLDN18.2-positive solid tumors (e.g., gastric/GEJ, pancreatic, esophageal adenocarcinoma, biliary tract cancers) after prior systemic therapy receive BL-M05D1, an IV CLDN18.2-targeting antibody–drug conjugate linking a cathepsin B–cleavable topoisomerase I inhibitor payload, given every 21 days. Key eligibility includes measurable disease, ECOG 0–1, adequate organ function, and prior appropriate targeted/immunotherapy for actionable biomarkers.

ClinicalTrials.gov ID: NCT07021066

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic PDAC, gastric/GEJ, or biliary tract cancers (ECOG 0–1) after at least one prior systemic therapy receive AZD4360 monotherapy. AZD4360 is an investigational CLDN18.2-targeted agent (modality not disclosed) in first-in-human dose escalation/expansion to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06921928

A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.

ClinicalTrials.gov ID: NCT07001592

A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.

ClinicalTrials.gov ID: NCT05332002

Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, well-differentiated (WHO grade 1–2), SSTR-positive GEP-NETs limited to liver/lymph nodes and eligible for cytoreductive surgery (R1 intent) receive perioperative 177Lu‑DOTATATE PRRT: two neoadjuvant cycles, surgery, then up to two postoperative cycles based on residual disease by 68Ga‑DOTATATE PET/CT. 177Lu‑DOTATATE is a radiolabeled somatostatin analog targeting SSTR2 to deliver beta-emitting lutetium‑177 to tumor cells; patients must have uniform SSTR expression, Ki‑67 ≤20%, ECOG 0–1, and be on stable octreotide LAR.

ClinicalTrials.gov ID: NCT04609592

A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with gastric or Siewert II/III GEJ adenocarcinoma with peritoneal-only metastases and low tumor burden (PCI ≤7) after response to systemic therapy undergo robotic cytoreductive gastrectomy followed by HIPEC with cisplatin (DNA crosslinking platinum) and docetaxel (microtubule-stabilizing taxane). Trial focuses on perioperative safety and recovery metrics in this minimally invasive approach compared with historical open standards.

ClinicalTrials.gov ID: NCT05753306

Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, recurrent, or unresectable gastric or GEJ adenocarcinoma (ECOG 0–1), including those previously treated with anti–PD-1 and with PD-L1 CPS/TPS ≥1 in the randomized cohort, receive pembrolizumab (PD-1 inhibitor) plus ramucirumab (VEGFR2 inhibitor) with paclitaxel (or nab-paclitaxel if hypersensitive), comparing two paclitaxel schedules. Key exclusions include significant cardiovascular/bleeding risks, uncontrolled autoimmune or pulmonary disease, active infections (HBV/HCV/HIV), and significant neuropathy.

ClinicalTrials.gov ID: NCT04069273